Literature DB >> 28910187

Sternal Route More Effective than Tibial Route for Intraosseous Amiodarone Administration in a Swine Model of Ventricular Fibrillation.

James M Burgert, Andre Martinez, Mara O'Sullivan, Dawn Blouin, Audrey Long, Arthur D Johnson.   

Abstract

OBJECTIVE: The pharmacokinetics of IO administered lipid soluble amiodarone during ventricular fibrillation (VF) with ongoing CPR are unknown. This study measured mean plasma concentration over 5 minutes, maximum plasma concentration (Cmax), and time to maximum concentration (Tmax) of amiodarone administered by the sternal IO (SIO), tibial IO (TIO), and IV routes in a swine model of VF with ongoing CPR.
METHODS: Twenty-one Yorkshire-cross swine were randomly assigned to three groups: SIO, TIO, and IV. Ventricular fibrillation was induced under general anesthesia. After 4 minutes in VF, 300 mg amiodarone was administered as indicated by group assignment. Serial blood specimens collected at 30, 60, 90, 120, 150, 180, 240, and 300 seconds were analyzed using high performance liquid chromatography with tandem mass spectrometry.
RESULTS: The mean plasma concentration of IV amiodarone over 5 minutes was significantly higher than the TIO group at 60 seconds (P = 0.02) and 90 seconds (P = 0.017) post-injection. No significant differences in Cmax between the groups were found (P <0.05). The Tmax of amiodarone was significantly shorter in the SIO (99 secs) and IV (86 secs) groups compared to the TIO group (215 secs); P = 0.002 and P = 0.002, respectively.
CONCLUSIONS: The SIO and IV routes of amiodarone administration were comparable. The TIO group took nearly three times longer to reach Tmax than the SIO and IV groups, likely indicating depot of lipid-soluble amiodarone in adipose-rich tibial yellow bone marrow. The SIO route was more effective than the TIO route for amiodarone delivery in a swine model of VF with ongoing CPR. Further investigations are necessary to determine if the kinetic differences found between the SIO and TIO routes in this study affect survival of VF in humans.

Entities:  

Keywords:  Amiodarone; bone marrow; intraosseous infusions; resuscitation; ventricular fibrillation

Mesh:

Substances:

Year:  2017        PMID: 28910187     DOI: 10.1080/10903127.2017.1358782

Source DB:  PubMed          Journal:  Prehosp Emerg Care        ISSN: 1090-3127            Impact factor:   3.077


  4 in total

1.  [Supraglottic airway devices and intraosseous access in the treatment of patients after out-of-hospital cardiac arrest : Do we use the wrong tool too often?]

Authors:  M Christ; K I von Auenmüller; T von den Benken; S Fessaras; W Dierschke; H-J Trappe
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-10-23       Impact factor: 0.840

2.  Impaired Pharmacokinetics of Amiodarone under Veno-Venous Extracorporeal Membrane Oxygenation: From Bench to Bedside.

Authors:  Mickaël Lescroart; Claire Pressiat; Benjamin Péquignot; N'Guyen Tran; Jean-Louis Hébert; Nassib Alsagheer; Nicolas Gambier; Bijan Ghaleh; Julien Scala-Bertola; Bruno Levy
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

3.  Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest.

Authors:  Mohamud R Daya; Brian G Leroux; Paul Dorian; Thomas D Rea; Craig D Newgard; Laurie J Morrison; Joshua R Lupton; James J Menegazzi; Joseph P Ornato; George Sopko; Jim Christenson; Ahamed Idris; Purav Mody; Gary M Vilke; Caroline Herdeman; David Barbic; Peter J Kudenchuk
Journal:  Circulation       Date:  2020-01-16       Impact factor: 29.690

Review 4.  Sternal Intraosseous Devices: Review of the Literature.

Authors:  Jared A Laney; Jonathan Friedman; Andrew D Fisher
Journal:  West J Emerg Med       Date:  2021-03-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.